Research Projects All Projects
Projects

Quick links

Development of anti-Lyme disease vaccine candidate

Project Title: „ Development of anti-Lyme disease vaccine candidate

Funding: European Regional Development Fund (ERDF), Measure 1.2.1. Specific support goal "To Increase the Private Sector Investments R&D"; measure 1.2.1.2. "Support for Improvement of Technology Transfer System" “Industry‑Driven Research”

Project Nr.: KC-PI-2017/84 

Technical and economic feasibility study and the development of commercialisation strategy that will be accomplished within the first 6 months (30 th January 2017 – 29 th July 2018)

Technical and economic feasibility study and the development of commercialisation strategy costs: 27 777,77 EUR

Principle Investigator: Dr. biol. K.Tārs

 

 

The aim of the project is development of anti-Lyme disease vaccine candidate. Within our previous projects, BMC researchers already have developed an anti-Lyme disease vaccine candidate, protectivity of which has been shown in animal models. Within the project VLP technology based anti-Lyme disease candidate will be investigated and improved.

The commercial end products of our project stage would be a licensable patent and a product up-scale technology licence.

During the 1st phase of the project, a technical and economic feasibility study and commercialisation strategy will be developed.

Information published 30.01.2018.

 

30.01.2018-30.04.2018

In the period from 30.01.2018-30.04.2018 the procurement regulations for procurement "Feasibility study and commercialization strategy development service " were prepared. The purpose of the service is to define the steps to develop a product or technology from conception to market introduction, and also to analyse the choice of a more advantageous solution between assigning the right to use industrial property to another person (licensing agreement, patent sale) or creating a new business on a scientific basis, and make recommendation what information should be prepared to get potential licensees or investment funds attention and offer them the technology. The above-mentioned procurement was announced on the website of the Procurement Monitoring Bureau on 20.03.2018.

KPMG Baltics Ltd. was recognized as the winner in the procurement.

Information published 27.04.2018.

 

01.05.2018-30.07.2018

During the reporting period continue work to the development of the Technically Economic feasibility study and the Commercialisation strategy with “KPMG Baltics”.

Published 30.07.2018.



Mājas lapas izstrādi finansēja ERAF 2.1.1.2. aktivitātes projekts Nr. 2010/0196/2DP/2.1.1.2.0/10/APIA/VIAA/004 "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".